Moderna Shares Plunge After Predicting Steep 2025 Sales Decline
The company's newer product, an RSV ( respiratory syncytial virus) vaccine, has also underperformed, contributing "minimal sales" in 2024. Analysts' concerns were heightened by the company's revised sales forecast for 2024, which projects $3 billion to $3.1 billion, falling at the low end of previous estimates.
Moderna stock plunges nearly 17% after company lowers 2025 sales forecast by $1 billion
Moderna now expects 2025 revenue to come in between $1.5 billion and $2.5 billion, most of which will come in the second half of the year.
Moderna Stock Plunges After Vaccine Sales Struggle
Shares of Moderna plunged 20% Monday after the vaccine maker slashed its forecast of full-year 2025 revenue, as sales of its vaccines against Covid-19 and respiratory syncytial virus continue to be sluggish.
Moderna cuts 2025 sales forecast by $1 bln on weak vaccine demand, shares tumble
Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) shot and weak demand for COVID-19 vaccines, sending its shares down more than 24% in early trading.
S&P 500 Gains and Losses Today: Moderna Plunges After Big Cut to Sales Forecast
Key Takeaways The S&P 500 ended 0.2% higher on Monday, Jan. 13, 2025, ahead of this week's inflation data and the first wave of earnings reports from the nation's biggest banks.Moderna shares plummeted after the biotech firm slashed its 2025 revenue guidance,
CDC upgrades its advisory on bird flu. Will Moderna’s stock get a boost?
CDC officials say medical professionals are seeing more patients whose illness cannot be traced back to an infected animal or ...
Is Moderna a Bad-News Buy for 2025?
At the healthcare conference, Moderna lowered expected 2025 revenue to the range of $1.5 billion to $2.5 billion -- down from ...
Moderna May Have The Best Shot At A Vaccine For Stomach Flu
Cases of norovirus infections are surging, but coming up with a way to prevent them has proven to be a challenge.
Moderna's Road To Stopping The Red
Moderna is down 80% from its 52-week high as revenues continue to fall and the new RSV vaccine has performed poorly. Read my ...
Why Moderna Stock Just Crashed 21%
Moderna 's ( MRNA -20.49%) sales are slowing down, and Moderna stock is going down -- a lot. The coronavirus vaccine maker's ...
Moderna surprises the Street by predicting a bigger-than-expected sales drop
Shares of Moderna tumbled Monday after the vaccine maker predicted a steeper-than-expected sales drop in the new year ...
Watch These Moderna Price Levels as Stock Plummets After Slashing 2025 Revenue Outlook
Moderna shares will likely remain under scrutiny after plunging nearly 17% Monday as the embattled drug maker slashed its ...
Monthly Prescribing Reference2d
Moderna Provides Update on Norovirus Vaccine Candidate
Moderna’s mRNA-1403 is a messenger RNA-based trivalent vaccine candidate designed to protect against multiple norovirus genotypes. Moderna provided an update on the status of its trial investigating a ...
Moderna Dropped by 20% This Week -- Is It a Smart Buy Right Now?
The main reason for this week's decline is that Moderna lowered its 2025 full-year revenue guidance, and by a wide margin.